Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: January 2022
Date of Report: January 4, 2022
Principal Executive Office: 117 Avenue de Luminy, 13009 Marseille, France
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves as a cover document for a press release (Exhibit 99.1) and does not contain embedded financial statements or numerical data.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. The document references a press release dated January 4, 2022, but the content of that release is not included in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to administrative details and the signature of the Chairman of the Executive Board and CEO, Mondher Mahjoubi.
Investor Verification Checklist
- Review the full text of the Press Release dated January 4, 2022 (referenced as Exhibit 99.1) to understand the specific corporate event triggering this filing.
- Verify the company's current cash position and runway by consulting the most recent Form 20-F or quarterly financial statements, as this filing contains no financial data.
- Confirm the status of the company's clinical pipeline or commercial developments mentioned in the associated press release.